A Preliminary Clinical Study on the Pharmacokinetics and Safety of Recombinant Anti-EGFR Human Mouse Chimeric Monoclonal Antibody Injection (CDP1) in Patients With Advanced Colorectal Cancer or Head and Neck Squamous Cell Carcinoma
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 05 Nov 2019
Price : $35 *
At a glance
- Drugs Cetuximab (Primary)
- Indications Colorectal cancer; Head and neck cancer; Squamous cell cancer
- Focus Pharmacokinetics
- Sponsors Dragonboat Biopharmaceutical
- 29 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 18 Mar 2019 Planned End Date changed from 1 Jun 2019 to 1 Dec 2019.
- 18 Mar 2019 Planned primary completion date changed from 1 Jan 2019 to 1 Sep 2019.